External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients

2014 ◽  
Vol 92 (6) ◽  
pp. 502-509 ◽  
Author(s):  
Rongfeng Fu ◽  
Min Xuan ◽  
Cuicui Lv ◽  
Liyan Zhang ◽  
Huiyuan Li ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Essential Thrombocythemia ◽  
Prognostic Score ◽  
External Validation ◽  
Large Cohort ◽  
Chinese Patients ◽  
International Prognostic Score

scholarly journals Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients

2016 ◽  
Vol 91 (4) ◽  
pp. 390-394 ◽  
Author(s):  
Mahnur Haider ◽  
Naseema Gangat ◽  
Terra Lasho ◽  
Ahmed K. Abou Hussein ◽  
Yoseph C. Elala ◽  
...  
Keyword(s):  
Essential Thrombocythemia ◽  
Mayo Clinic ◽  
Prognostic Score ◽  
International Prognostic Score

scholarly journals Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients

2021 ◽  
Vol 7 (2) ◽  
pp. 205521732110227
Author(s):  
Friederike Held ◽  
Sudhakar Reddy Kalluri ◽  
Achim Berthele ◽  
Ana-Katharina Klein ◽  
Markus Reindl ◽  
...  
Keyword(s):  
Time Course ◽  
Neurological Diseases ◽  
External Validation ◽  
Diagnostic Value ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Large Cohort ◽  
Wide Range ◽  
Neurological Patients ◽  
A Cell ◽  
Nosological Entity

Background Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes have been reported to be associated with MOG-Ab. Objective To investigate the seroprevalence of MOG-Ab under consideration of demographics, disease entities and time course in a large cohort of unselected neurological patients. Methods Blood samples of 2.107 consecutive adult neurologic patients admitted to our department between 2016-2017 were tested for MOG-Ab using a cell-based assay. MOG-Ab persistence was analyzed in follow-up samples. External validation was performed in two independent laboratories. Results We found MOG-Ab in 25 of 2.107 (1.2%) patients. High antibody ratios were mostly associated with NMOSD and MOG-AD phenotype (5/25). Low ratios occurred in a wide range of neurological diseases, predominantly in other demyelinating CNS diseases (5/25) and stroke (6/25). MOG-Ab persistence over time was not confined to NMOSD and MOG-AD phenotype. Conclusion The present study demonstrates the occurrence of MOG-Ab in a wide range of neurological diseases. Only high MOG-Ab ratios were associated with a defined clinical phenotype, but low MOG-Ab ratios were not. The diagnostic value of low MOG-Ab is thus highly limited.

scholarly journals The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 671
Author(s):  
Margherita Rimini ◽  
Pierfrancesco Franco ◽  
Berardino De Bari ◽  
Maria Giulia Zampino ◽  
Stefano Vagge ◽  
...  
Keyword(s):  
High Risk ◽  
Cancer Patients ◽  
Anal Cancer ◽  
Prognostic Score ◽  
Univariate Analysis ◽  
External Validation ◽  
Risk Groups ◽  
Anal Squamous Cell Carcinoma ◽  
Predictors Of Response ◽  
Risk Patients

Anal squamous cell carcinoma (SCC) is a rare tumor, and bio-humoral predictors of response to chemo-radiation (CT-RT) are lacking. We developed a prognostic score system based on laboratory inflammation parameters. We investigated the correlation between baseline clinical and laboratory variables and disease-free (DFS) and overall (OS) survival in anal SCC patients treated with CT-RT in five institutions. The bio-humoral parameters of significance were included in a new scoring system, which was tested with other significant variables in a Cox’s proportional hazard model. A total of 308 patients was included. We devised a prognostic model by combining baseline hemoglobin level, SII, and eosinophil count: the Hemo-Eosinophils Inflammation (HEI) Index. We stratified patients according to the HEI index into low- and high-risk groups. Median DFS for low-risk patients was not reached, and it was found to be 79.5 months for high-risk cases (Hazard Ratio 3.22; 95% CI: 2.04–5.10; p < 0.0001). Following adjustment for clinical covariates found significant at univariate analysis, multivariate analysis confirmed the HEI index as an independent prognostic factor for DFS and OS. The HEI index was shown to be a prognostic parameter for DFS and OS in anal cancer patients treated with CT-RT. An external validation of the HEI index is mandatory for its use in clinical practice.

Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages

2016 ◽  
Vol 57 (8) ◽  
pp. 1839-1847 ◽  
Author(s):  
Ljubomir R. Jakovic ◽  
Biljana S. Mihaljevic ◽  
Bosko M. Andjelic ◽  
Andrija D. Bogdanovic ◽  
Maja D. Perunicic Jovanovic ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Prognostic Value ◽  
Prognostic Score ◽  
Tumor Associated Macrophages ◽  
International Prognostic Score

Mo1434 Natural History of Pancreatic Intraductal Papillary Mucinous Neoplasms: Clinical Evaluation of Sendai Criteria in a Large Cohort of Patients

2014 ◽  
Vol 79 (5) ◽  
pp. AB436
Author(s):  
Emanuele Dabizzi ◽  
Maria C. Petrone ◽  
Mariaemilia Traini ◽  
Sabrina G. Testoni ◽  
Pier Alberto Testoni ◽  
...  
Keyword(s):  
Natural History ◽  
Clinical Evaluation ◽  
Large Cohort ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms ◽  
History Of ◽  
Sendai Criteria

scholarly journals Development and validation of a prognostic model for early triage of patients diagnosed with COVID-19

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chansik An ◽  
Hyun Cheol Oh ◽  
Jung Hyun Chang ◽  
Seung-Jin Oh ◽  
Jung Mo Lee ◽  
...  
Keyword(s):  
Prognostic Score ◽  
External Validation ◽  
Vital Signs ◽  
Underlying Disease ◽  
Test Results ◽  
Additional Information ◽  
Patient Will ◽  
National Cohort ◽  
Evaluation Metric ◽  
Development And Validation

AbstractWe developed a tool to guide decision-making for early triage of COVID-19 patients based on a predicted prognosis, using a Korean national cohort of 5,596 patients, and validated the developed tool with an external cohort of 445 patients treated in a single institution. Predictors chosen for our model were older age, male sex, subjective fever, dyspnea, altered consciousness, temperature ≥ 37.5 °C, heart rate ≥ 100 bpm, systolic blood pressure ≥ 160 mmHg, diabetes mellitus, heart disease, chronic kidney disease, cancer, dementia, anemia, leukocytosis, lymphocytopenia, and thrombocytopenia. In the external validation, when age, sex, symptoms, and underlying disease were used as predictors, the AUC used as an evaluation metric for our model’s performance was 0.850 in predicting whether a patient will require at least oxygen therapy and 0.833 in predicting whether a patient will need critical care or die from COVID-19. The AUCs improved to 0.871 and 0.864, respectively, when additional information on vital signs and blood test results were also used. In contrast, the protocols currently recommended in Korea showed AUCs less than 0.75. An application for calculating the prognostic score in COVID-19 patients based on the results of this study is presented on our website (https://nhimc.shinyapps.io/ih-psc/), where the results of the validation ongoing in our institution are periodically updated.

Sign in / Sign up

Export Citation Format

Share Document